Get started
Author

Katherine E. Redd Bowman

Observed names: Katherine E Redd Bowman, Katherine Redd Bowman
ORCID: 0000-0002-9762-2409
Observed ORCID: 0000-0002-9762-2409
OpenAlex ID: A5046907715
The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer
2023 · Bryce Wallis, Katherine Redd Bowman, et al. · Biomolecules · 59
PDF
Advances in Delivery Vectors for Gene Therapy in Liver Cancer
2019 · Katherine E Redd Bowman, Phong Lu, et al. · Therapeutic Delivery · 24
p53-Bad: A Novel Tumor Suppressor/Proapoptotic Factor Hybrid Directed to the Mitochondria for Ovarian Cancer Gene Therapy
2019 · Phong Lu, Katherine E. Redd Bowman, et al. · Molecular Pharmaceutics · 21
PDF
Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer
2019 · Katherine Redd Bowman, Ji Hoon Kim, et al. · Journal of Ovarian Research · 12
PDF
Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
2019 · Phong Lu, Erica R. Vander Mause, et al. · Journal of Ovarian Research · 9
PDF
p53-Bad* Fusion Gene Therapy Induces Apoptosis In Vitro and Reduces Zebrafish Tumor Burden in Hepatocellular Carcinoma
2022 · Katherine E. Redd Bowman, Lisa Ahne, et al. · Molecular Pharmaceutics · 5
PDF
Mitochondrially Targeted p53-Bad* Fusion Gene Therapy Promotes Apoptosis in Hepatocellular Carcinoma by Pan-Bcl-2 Inhibition
2025 · Braxten D. Hornsby, Julius K. K. Tuekpe, et al. · Molecular Pharmaceutics · 4
p53-Bad* in a Hepatocellular Carcinoma Mouse Model
2023 · Katherine Redd Bowman, Phong Lu, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Works count: 8
Citation count: 134
H-index: 5
I10-index: 4
Year
Topic
Type